Neoadjuvant camrelizumab (an anti-PD-1 antibody) plus chemotherapy or apatinib (a VEGFR-2 inhibitor) for initially unresectable stage II–III non-small-cell lung cancer: a multicentre, two-arm, phase 2 exploratory studyHaoran Xia, Gening Jiang, Liangdong Sun et al.|Signal Transduction and Targeted Therapy|2024Cited by 30
Anti-PD1 based precision induction therapy in unresectable stage III non-small cell lung cancer: a phase II umbrella clinical trialChengxiang Yi, Peng Zhang, Dongliang Bian et al.|Nature Communications|2025Cited by 13